vs
Side-by-side financial comparison of EXPONENT INC (EXPO) and Prenetics Global Ltd (PRE). Click either name above to swap in a different company.
EXPONENT INC is the larger business by last-quarter revenue ($166.3M vs $92.0M, roughly 1.8× Prenetics Global Ltd).
Exponent, Inc. is an American engineering and scientific consulting firm. Exponent has a team of scientists, physicians, engineers, and business consultants which performs research and analysis in more than 90 technical disciplines. The company operates 20 offices in the United States and five offices overseas.
Prenetics (NASDAQ:PRE) is a health sciences company headquartered in Hong Kong, with a presence in the United States. It focuses on early detection, prevention, and treatment of diseases, particularly cancer.
EXPO vs PRE — Head-to-Head
Income Statement — Q1 FY2027 vs Q1 FY2023
| Metric | | |
|---|---|---|
| Revenue | $166.3M | $92.0M |
| Net Profit | $29.6M | — |
| Gross Margin | — | 39.2% |
| Operating Margin | 24.9% | — |
| Net Margin | 17.8% | — |
| Revenue YoY | 14.3% | — |
| Net Profit YoY | 11.0% | — |
| EPS (diluted) | $0.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $166.3M | — | ||
| Q4 25 | $147.1M | — | ||
| Q3 25 | $142.0M | — | ||
| Q2 25 | $145.5M | — | ||
| Q1 25 | $136.8M | — | ||
| Q3 24 | $136.3M | — | ||
| Q2 24 | $140.5M | — | ||
| Q1 23 | — | $92.0M |
| Q1 26 | $29.6M | — | ||
| Q4 25 | $28.0M | — | ||
| Q3 25 | $26.6M | — | ||
| Q2 25 | $26.6M | — | ||
| Q1 25 | $23.6M | — | ||
| Q3 24 | $26.0M | — | ||
| Q2 24 | $29.2M | — | ||
| Q1 23 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | 39.2% |
| Q1 26 | 24.9% | — | ||
| Q4 25 | 19.7% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 19.9% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 25.4% | — | ||
| Q1 23 | — | — |
| Q1 26 | 17.8% | — | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | 18.3% | — | ||
| Q1 25 | 17.2% | — | ||
| Q3 24 | 19.1% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 23 | — | — |
| Q1 26 | $0.59 | — | ||
| Q4 25 | $0.55 | — | ||
| Q3 25 | $0.52 | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.45 | — | ||
| Q3 24 | $0.50 | — | ||
| Q2 24 | $0.57 | — | ||
| Q1 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.3M | — |
| Total Assets | $687.4M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.6M | — | ||
| Q4 25 | $207.4M | — | ||
| Q3 25 | $231.8M | — | ||
| Q2 25 | $245.1M | — | ||
| Q1 25 | $258.9M | — | ||
| Q3 24 | $219.7M | — | ||
| Q2 24 | $203.3M | — | ||
| Q1 23 | — | — |
| Q1 26 | $338.3M | — | ||
| Q4 25 | $402.9M | — | ||
| Q3 25 | $427.8M | — | ||
| Q2 25 | $441.4M | — | ||
| Q1 25 | $421.1M | — | ||
| Q3 24 | $410.3M | — | ||
| Q2 24 | $393.2M | — | ||
| Q1 23 | — | — |
| Q1 26 | $687.4M | — | ||
| Q4 25 | $761.4M | — | ||
| Q3 25 | $759.4M | — | ||
| Q2 25 | $763.2M | — | ||
| Q1 25 | $777.3M | — | ||
| Q3 24 | $744.1M | — | ||
| Q2 24 | $709.2M | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXPO
| Revenues before reimbursements | $151.8M | 91% |
| Reimbursements | $14.5M | 9% |
PRE
Segment breakdown not available.
